Regeneron Beats Q2 Sales Estimates
This is a U.S. news story, published by Yahoo Finance, that relates primarily to Regeneron Pharmaceuticals news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Drugmaker Regeneron Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Dupixent sales news, cheaper biosimilars news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
rival Swiss drugmaker RocheReuters
•Regeneron beats quarterly results on strong demand for eczema, eye treatments
81% Informative
Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit.
U.S. sales of Eylea , jointly developed with Bayer AG , rose 2% to $1.53 billion in the reported quarter from a year earlier .
Regeneron 's anti-inflammatory drug, Dupixent , posted quarterly sales of $3.56 billion .
VR Score
92
Informative language
99
Neutral language
72
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links